

In the Specification:

Please amend the specification by inclusion of the attached Sequence Listing, both in printed form and computer readable form.

REMARKS

Claims 1-17 are pending in the application. In response to the Office Communication and the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, and Raw Sequence Listing Error Summary (found in paper no. 13), Applicants submit a substitute Sequence Listing in printed form and computer-readable form and the appropriate Statement under 37 C.F.R. 1.821-825. No new matter has been added.

The Office Communication sent by facsimile on June 26, 2001 (paper no. 14) expressly vacated the previous Office Communication of May 31, 2001 (paper no. 13), stating that the latter had been sent by the Examiner by an inadvertent error. Applicants, therefore, now respond to the June 26, 2001 Office Communication (paper no. 14), which asserts that the amended sequence listing filed October 12, 2000 contained further errors. Applicants hereby submit a substitute sequence listing which corrects all such errors.


CONCLUSION

Applicants respectfully request consideration and allowance of the pending claims. Early and favorable notification to that effect is earnestly solicited. Should the Examiner have any comments, Applicants urge the Examiner to call the undersigned at the indicated phone number.

Please continue to direct all correspondence relating to this application to:

Alisa A. Harbin, Esq.
Chiron Corporation
Intellectual Property-R440
P.O. Box 8097
Emeryville, CA, 94662-8097
(510) 923-2708.

Respectfully submitted,



Mark J. Rosen
Registration No. 39,822

Date: July 26, 2001

WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
(215) 568-3100